MALIGNANCY

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This study looks at a rare, often fatal disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers want to learn how the disease works and test several experimental drug combinations, including zidovudine, valganciclovir, bortezomib, and…

This study looks at whether adding a community health worker to standard care can improve quality of life and advance care planning for African American patients with advanced cancer. About 160 patients and their caregivers will take part. The goal is to see if this extra support…

This study looks at why people who have had an organ transplant are more likely to get cancer. Researchers will combine existing health records from over 85,000 transplant patients in England to track cancer cases and deaths. The goal is to better understand risks and improve car…

This study was designed to track how the immune system recovers after CAR-T cell therapy and to test a pneumococcal vaccine (PCV-21) in these patients. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any participants were…

This study collects medical information and biological samples from 32 cancer patients receiving immunotherapy. The goal is to better understand why some patients develop immune-related side effects and how to manage them. Researchers hope this knowledge will improve treatment sa…

This study compares different outreach methods to see which works best for getting African American patients to join early phase cancer treatment trials. About 134 patients and their doctors will take part. The goal is to learn how to make cancer research more inclusive.

This study was designed to see if a special PET/CT imaging agent called 68Ga-FAPI-46 could help predict how well solid tumor cancers respond to antibody-based therapy. Participants would have received the agent and a PET/CT scan before starting treatment, then be followed for up …